C4 Therapeutics, Inc.
CCCCStock
$3.58+80.09%52W
Market Cap$395.83M
P/E—
Div yield—
Beta2.91
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)61.71%
Price vs S&P 500 (4W)-1.64%
VGM Score49.99
Market Capitalization$395.83M
Earnings Surprise History
Q1 26-0.20est. -0.38
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.29
4.29
4.29
4.29
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CCCCC4 Therapeutics, Inc. | C | D | B | $3.58 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies designed to address difficult-to-treat cancers and other diseases. Its proprietary TORPEDO platform enables the efficient design of small-molecule degraders that leverage the body's natural protein recycling system to overcome drug resistance and tackle undruggable targets. The company's pipeline includes three oncology programs: Cemsidomide, CFT1946, and CFT8919.